Gabapentin
Product Images NDC 68788-7049

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-7049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 01)

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 01)
Table showing Gabapentin dosage based on renal function measured by creatinine clearance (mL/min). It provides total daily dose ranges (mg/day) and dose regimens in mg for various frequencies (TID, BID, QD) by clearance categories. Also includes post-hemodialysis supplemental dosing instructions. Abbreviations for dosing frequencies explained, with footnotes on dose adjustments for low clearance and hemodialysis patients.*
FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 02)

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 02)
A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients is shown. This text is likely part of dosing or pharmacokinetic information for Gabapentin by Preferred Pharmaceuticals Inc.*
FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 03)

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 03)
A table titled 'TABLE 2 Risk by Indication for Antiepileptic Drugs in the Pooled Analysis' showing comparative data for placebo versus drug patients across indications (Epilepsy, Psychiatric, Other). It includes columns for events per 1000 patients, relative risk, and risk difference in additional drug patients with events per 1000 patients.*
FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 04)

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 04)
Chemical structure of Gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*
FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 05)

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 05)
A line graph depicting mean pain scores over eight weeks comparing Gabapentin 3600 mg/day to a placebo. The x-axis shows weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing trend in pain scores, while placebo remains relatively stable.*
FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 06)

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 06)
A line graph depicting mean pain scores over a 7-week period comparing placebo with Gabapentin dosed at 1800 mg/day and 2400 mg/day. The x-axis represents weeks divided into a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows the mean pain score ranging from 0 to 10.*
FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 07)

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 07)
A bar graph titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing two studies. Study 1 compares placebo (12%) to GBP 3600 (29%). Study 2 compares placebo (14%) to GBP 1800 (32%) and GBP 2400 (34%). Statistical significance is indicated with p-values less than 0.01 and 0.001.*
FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 08)

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 08)
A scatter plot comparing differences (%) by daily dose (mg) for three studies labeled as STUDY a, STUDY b, and STUDY c. The x-axis represents daily dose in milligrams (600 to 1800 mg), and the y-axis represents difference in percentage (2% to 22%). Data points for each study show varying values across three dose levels.*
FDA Label Image

Gabapentin Capsules, Usp 600mg (54f184de Ba3e 4db8 Ae88 B4c06263df79 09)

Gabapentin Capsules, Usp 600mg (54f184de Ba3e 4db8 Ae88 B4c06263df79 09)
Label for Gabapentin tabs 600mg (CV) by Preferred Pharmaceuticals Inc. The label is yellow with black text, identifying the product as generic for Neurontin. It notes each tablet contains 600mg Gabapentin. Manufacturer listed as Cipla USA, Inc. with storage instructions and space for lot, batch, expiration date, and insurance details. Instructions in English and Spanish include dosage timing but are not fully filled.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.